Brind.
  1. Aquestive, a specialty pharmaceutical company, outperformed the S&P 500 gain this year.

Aquestive, a specialty pharmaceutical company, seeks international regulatory approval in Canada.

1 report, 1 independent Updated Jul 15
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Aquestive, a specialty pharmaceutical company, seeks international regulatory approval in Canada.

Who's involved

What this event is mainly about
Aquestive (United States)

Keep exploring

Part of

Aquestive, a specialty pharmaceutical company, outperformed the S&P 500 gain this year. All 1 developments

The entities involved

Coverage

Newest first; wire copies grouped
  • GlobeNewswireAquestive Therapeutics Provides International Expansion Update for Anaphylmâ„¢ (epinephrine) Sublingual Film New Drug Submission meeting scheduled with Health Canada for the third quarter of 2025 Initi